COMMUNIQUÉS West-GlobeNewswire

-
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
07/04/2025 -
European Commission approves Johnson & Johnson’s subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
07/04/2025 -
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer
07/04/2025 -
Angelini Ventures Appoints Seasoned Life Sciences Investor, Dr. Regina Hodits, as Managing Director
07/04/2025 -
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
06/04/2025 -
Scarless MTF Breast Augmentation Performed by Seattle Plastic Surgeon
05/04/2025 -
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
05/04/2025 -
Arialief Reviews (SHOCKING REPORT!) Is This Sciatic Nerve Relief Supplement Safe or Overhyped Hoax?
05/04/2025 -
PacBio Grants Equity Incentive Award to New Employee
05/04/2025 -
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
04/04/2025 -
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
04/04/2025 -
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025 -
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/04/2025 -
Breaking Barriers in Autism: European Wellness Biomedical Group Unveils Bioregenerative Breakthroughs with Prof. Mike Chan
04/04/2025 -
Edesa Biotech Announces Chief Financial Officer Transition
04/04/2025 -
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025 -
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025 -
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/04/2025 -
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025
Pages